NMOSD acute attack: Understanding, treatment and innovative treatment prospect
- PMID: 32987231
- DOI: 10.1016/j.jneuroim.2020.577387
NMOSD acute attack: Understanding, treatment and innovative treatment prospect
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is a group of severe inflammatory demyelinating disorders of the central nervous system that involves the optic nerve and spinal cord. Currently the therapeutic options for an acute attack in NMOSD are limited and rarely characterized in clinical studies. This review discussed the overall characteristics of acute attack of NMOSD, related risk factor, prognosis and management. Considering the huge unmet needs and the emergence of new therapeutic targets, we also reviewed innovative treatments that might alleviate attack damage, along with the challenges to evaluate new drug for acute attack in NMOSD.
Keywords: Acute attack; Innovative treatment; Neuromyelitis optica spectrum disorder; Risk factor; Severe attack.
Copyright © 2020 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare no conflict of interest.
Similar articles
-
[Neuromyelitis optica].Medicina (B Aires). 2019;79 Suppl 3:60-65. Medicina (B Aires). 2019. PMID: 31603846 Review. Spanish.
-
Monoclonal antibody therapy for neuromyelitis optica spectrum disorder: current and future.Int J Neurosci. 2017 Aug;127(8):735-744. doi: 10.1080/00207454.2016.1242587. Epub 2016 Oct 14. Int J Neurosci. 2017. PMID: 27680606 Review.
-
Neuromyelitis Optica (Devic's Syndrome): an Appraisal.Curr Rheumatol Rep. 2016 Aug;18(8):54. doi: 10.1007/s11926-016-0599-3. Curr Rheumatol Rep. 2016. PMID: 27402111 Review.
-
Controversies in the management of neuromyelitis optica spectrum disorder.Expert Rev Neurother. 2019 Nov;19(11):1127-1133. doi: 10.1080/14737175.2019.1648210. Epub 2019 Aug 12. Expert Rev Neurother. 2019. PMID: 31339052 Review.
-
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi: 10.1212/NXI.0000000000000841. Print 2020 Sep 3. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32820020 Free PMC article. Review.
Cited by
-
Neuromyelitis optica spectrum disorders and anti-myelin oligodendrocyte glycoprotein positive optic neuropathies.Int J Ophthalmol. 2022 Jul 18;15(7):1095-1107. doi: 10.18240/ijo.2022.07.09. eCollection 2022. Int J Ophthalmol. 2022. PMID: 35919317 Free PMC article.
-
Breast cancer-associated paraneoplastic neuromyelitis optica with cervical cord compression and spondylosis requiring laminectomy: A case report.SAGE Open Med Case Rep. 2023 Sep 1;11:2050313X231198322. doi: 10.1177/2050313X231198322. eCollection 2023. SAGE Open Med Case Rep. 2023. PMID: 37667745 Free PMC article.
-
FcRn Inhibitor Therapies in Neurologic Diseases.CNS Drugs. 2024 Jun;38(6):425-441. doi: 10.1007/s40263-024-01090-3. Epub 2024 May 9. CNS Drugs. 2024. PMID: 38724842 Review.
-
Analysis of Predictive Risk Factors in Aquaporin-4-IgG Positive Highly Active Neuromyelitis Optica Spectrum Disorders.Front Neurol. 2021 Aug 26;12:731835. doi: 10.3389/fneur.2021.731835. eCollection 2021. Front Neurol. 2021. PMID: 34512539 Free PMC article.
-
Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders.Orphanet J Rare Dis. 2024 Dec 21;19(1):483. doi: 10.1186/s13023-024-03501-6. Orphanet J Rare Dis. 2024. PMID: 39709432 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources